Bio-Fit Orthotics
Integrated biopharmaceutical company combining discovery, development, manufacturing and commercial operations. Focus areas include small-molecule drugs, biologics and antibody–drug conjugates (ADCs). The organization operates R&D centers in China and the United States, multiple GMP manufacturing sites for biologics, oral formulations and APIs/intermediates, and conducts IND-enabling studies and early‑phase clinical programs with pharmacovigilance and regulatory submission activities.
Industries
Nr. of Employees
small (1-50)
Bio-Fit Orthotics
Administrative and marketing headquarters: Chengdu High‑tech International Plaza, Building B, 10th Floor (source: site map and group structure)
Products
Clinical-stage pipeline of multispecific antibodies and ADCs
A portfolio of clinical-stage therapeutic antibody programs, including multispecific antibodies and antibody–drug conjugates progressed into Phase I/II clinical trials.
Portfolio of generic and specialty pharmaceuticals
Manufactured products and product registrations across pediatric medicines, cardiovascular, anesthesiology/critical care and chronic disease therapeutics in oral and injectable forms.
Clinical-stage pipeline of multispecific antibodies and ADCs
A portfolio of clinical-stage therapeutic antibody programs, including multispecific antibodies and antibody–drug conjugates progressed into Phase I/II clinical trials.
Portfolio of generic and specialty pharmaceuticals
Manufactured products and product registrations across pediatric medicines, cardiovascular, anesthesiology/critical care and chronic disease therapeutics in oral and injectable forms.
Services
On-site manufacturing and process development services for chemical drugs, oral formulations, injectables, biologics and ADCs under GMP standards.
On-site manufacturing and process development services for chemical drugs, oral formulations, injectables, biologics and ADCs under GMP standards.
Expertise Areas
- Oncology biologics development
- Multispecific antibody engineering
- Antibody–drug conjugate development
- Early‑phase clinical development (Phase I/II)
Key Technologies
- Multispecific antibody platforms
- Antibody–drug conjugation platforms
- cGMP biologics manufacturing
- Small‑molecule formulation and oral dosage manufacturing
News & Updates
Senior clinical leader appointed to lead global clinical strategy for the oncology pipeline and accelerate international clinical development.
Company recognized as a national enterprise technology center by relevant national agencies, reflecting validated innovation capacity.
Reported progression of multiple antibody and ADC programs into Phase I/II clinical trials during 2021.
Multiple-year inclusion in national lists for pharmaceutical R&D industrial performance and innovation capability.
Member of national pediatric drug R&D alliance and recipient of provincial/national innovation and patent‑volume rankings.
Senior clinical leader appointed to lead global clinical strategy for the oncology pipeline and accelerate international clinical development.
Company recognized as a national enterprise technology center by relevant national agencies, reflecting validated innovation capacity.
Reported progression of multiple antibody and ADC programs into Phase I/II clinical trials during 2021.
Multiple-year inclusion in national lists for pharmaceutical R&D industrial performance and innovation capability.
Member of national pediatric drug R&D alliance and recipient of provincial/national innovation and patent‑volume rankings.